Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398624 | 0.81 | MAPT (0.53) | TSHRNPSR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL28787105 | 0.81 | MAPT (0.53) | TSHRNPSR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL7201340 | 0.80 | TSHR (0.51) | TSHRNPSR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1654888 | 0.77 | CA1 (0.41) | TSHRNPSR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1325110 | 0.73 | TSHR (0.48) | TSHRNPSR1EDNRA | |
| SCHEMBL10670425 | 0.73 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9608966 | 0.72 | TSHR (0.67) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL21689895 | 0.72 | TSHR (0.67) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL30230052 | 0.72 | TSHR (0.67) | TSHRNPSR1PRCPGAAMAPT | |
| SCHEMBL17231978 | 0.72 | TSHR (0.67) | TSHRNPSR1PRCPGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757604-B1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | ASTELLAS PHARMA INC (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7829715-B2 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105795-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | ASTELLAS PHARMA INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | SUCNR1, GLS, CACNA1S | TSHR 3759/4885NPSR1 461/4885GRIN2D 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.